Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13946079 | 1.00 | CYP2D6 (0.40) | CYP2D6KCNH2HRH3ALDH1A1TDP1 | |
| SCHEMBL20620367 | 0.88 | CYP2D6 (0.34) | CYP2D6KCNH2HRH3ALDH1A1TDP1 | |
| SCHEMBL14804459 | 0.87 | HRH3 (0.46) | CYP2D6KCNH2HRH3ALDH1A1TDP1 | |
| SCHEMBL4099236 | 0.83 | HRH3 (0.50) | CYP2D6KCNH2HRH3 | |
| SCHEMBL21025310 | 0.83 | HRH3 (0.50) | CYP2D6KCNH2HRH3 | |
| SCHEMBL1104717 | 0.83 | HRH3 (0.50) | CYP2D6KCNH2HRH3 | |
| SCHEMBL16285871 | 0.77 | CYP2D6 (0.37) | CYP2D6KCNH2HRH3 | |
| SCHEMBL16285874 | 0.77 | CYP2D6 (0.37) | CYP2D6KCNH2HRH3 | |
| SCHEMBL12868931 | 0.77 | CYP2D6 (0.37) | CYP2D6KCNH2HRH3 | |
| SCHEMBL23034541 | 0.76 | HRH3 (0.38) | CYP2D6KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385065-B2 | Antibacterial compounds | REDX PHARMA PLC (GB) | 2019-08-20 | — | — | US | disclosed |
| US-20170158708-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158708-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158708-A1 | ANTIBACTERIAL COMPOUNDS | ABCC1, SLC11A2, NQO2 | CYP2D6 395/4885KCNH2 2177/4885HRH3 3829/4885 |
| US-10385065-B2 | Antibacterial compounds | ABCC1, SLC11A2, NQO2 | CYP2D6 395/4885KCNH2 2177/4885HRH3 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.